Novo Nordisk CEO Lars Fruergaard Jørgensen will defend the prices of his company’s mega-blockbuster obesity and Type 2 diabetes medicines Tuesday on Capitol Hill. The hearing, before the Senate Committee on Health,

U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand coverage of Novo Nordisk's popular diabetes and weight-loss medicines if the company lowered the list prices.

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies.